Managing type-2 diabetes in primary care in south camden - a focus on insulin conversion.

Slides:



Advertisements
Similar presentations
A Resource for Glycaemic management in Type 2 DM Hypoglycaemia is dangerous: Beware in Elderly/RF/CVS risk Sulphonureas need education to avoid risk Do.
Advertisements

A Resource for Glycaemic management in Diabetes key messages Hypoglycaemia is dangerous: Beware in elderly/RF/CVS risk Sulphonylureas need education to.
Monitoring diabetes Diabetes Outreach (March 2011)
No difference between different types of 3 rd line agent Meta analysis. 19 Articles, c 5k patients Cross et al Ann Int Med 2011.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
4-T Final Three-year Results Slides © University of Oxford Diabetes Trials Unit  4-T slides are copyright and remain the property of the University of.
Changes in levels of haemoglobin A 1c during the first 6 years after diagnosis of clinical type 2 diabetes Clinical implications Niels de Fine Olivarius.
JBS2 Some highlights from the JBS2 guidelines on prevention of cardiovascular disease in clinical practice Jim McMorran GP trainer Visiting Senior Clinical.
Insulin initiation OPTIMISING Glycaemic control and Weight Dr C Rajeswaran Consultant Physician Diabetes & Endocrinology Mid Yorkshire NHS Trust.
…in an academic collaboration with ISRCTN
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Managing Diabetes Medications. Topics What medications are available to –Manage diabetes? –Lower blood pressure? –Improve cholesterol? How can you keep.
Looking after your diabetes Dr Gill Hood North Thames Clinical Research Network
Clinical Protocol Using Insulin Pump Easy Guideline for Initiating Insulin Pumps on Type 2 Diabetes Patients.
A joint investigation by Channel 4 News and the BMJ reveals the NHS spends tens of millions more than necessary on modern insulins to treat diabetes despite.
DIABETES With All My Heart Presented by: Regina Weitzman, MD.
LONG TERM BENEFITS OF ORAL AGENTS
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
TEST/CHECK A1C O Fasting blood glucose check O Post-prandial blood glucose check O (1-2 hours after a meal) Blood pressure OBlood pressure O LDL cholesterol.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
1. Public Awareness Survey on 2,000 People with Diabetes (Fall 2001)  Findings: –68% do not consider cardiovascular disease to be complication of diabetes.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Insulin in Primary Care Dr Saqib Mahmud, MRCP(UK), MRCGP.
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Management of Type 2 Diabetes New Zealand Guidelines Group.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Rationale, Study Design & Study Population
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Glycemic Control: When the Lower is Not the “Better”?
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
Glucose Control and Monitoring
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Company Confidential © 2012 Eli Lilly and Company Prescribing human insulin: What do the guidelines say and what does this mean in practice? Speaker name.
Evaluating the Medical Evidence ​ A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.
Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.
Diabetes Aspects of the Local Enhanced Service Dr Mark Barrett Dr Jeremy Sandford Dr Aythen Elkindi.
NICE/BHS Hypertension Guideline Review 28 June 2006 John Barker ESH Clinical Hypertension Specialists European Society of Hypertension Specialist Accreditation.
Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.
Insulin Initiation With NovoMix30
Diabetes: Beyond Sugar. CHAOS C - Coronary artery disease H - Hyper-tension, -glycaemia, -insulinaemia A - Atherosclerosis O - Obesity S - Stroke.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2006 年 12 月 14 日 8:20-8:50 B 棟8階 カンファレンス室.
Primary Care Prescribing for Type 2 Diabetes Dr. David Jenkins Worcestershire Royal Hospital.
Angela Aziz Donnelly April 5, 2016
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
Prevention of diabetes complications The alphabet strategy.
Diabetes Learning Event 7th October 2016
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Associate Professor Medha Munshi
Copyright © 2017 American Academy of Pediatrics.
Prevention and Management of Diabetes Mellitus and its Complications
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Diabetes Health Status Report
Monitoring in Type 2 Diabetes
Statin Class in Session
Type 2 diabetes.
Statin Class in Session
DiRECT (Diabetes Remission Clinical Trial)
Primary Care Diabetes Dr Bruce Davies 02/01/2019.
Primary Care Diabetes Dr Bruce Davies 02/01/2019
Major classes of drugs to reduce lipids
Type 2 Diabetes Subgroup
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

managing type-2 diabetes in primary care in south camden - a focus on insulin conversion

Questions you want answering 2 minutes managing type-2 diabetes in primary care

Support materials General Whittington guidelines South camden guidelines – a local version RCN booklet Handouts All the material is on the website support xxxxxx Virtual referrals Dr Hurel:

Why do we need to take on diabetes?

WHAT DO OUR LOCAL GUIDELINES SAY? Screening General education Controlling risk factors Smoking BP Cholesterol Lowering glucose diet orals insulin Managing complications

General Message 1 Drug company focus on product A versus product B is misguided The basic drugs work fairly well – failures in care are rarely about choosing the right treatment The main problem is not giving an appropriate amount of simple but effective treatment

General Message 2 Effort on improving vascular risk factor control saves more lives than glucose control Glucose control is important too

Vascular Risk Factor Control Smoking - …….. BP – if mean of last 3 over 135/75 then needs more treatment now Lipids – if raised then needs more Aspirin - consider for all if CHD risk>15%

Simple step ladders e.g. lipids Diet only Simvastatin 20mg Simvastatin 40mg Atorvastatin 40mg Atorvastatin 40mg & Ezetemibe10mg If not controlled then test every 3 months If shows not controlled then move to next step If controlled then test annually

Insulin Who What How Adjusting

Usual slides on starting insulin here

Head on trials comparing regimens

Just reported 1 st year results of a 3 year trial No systematic difference between any – more effect always associated with more side effects Commentary stresses need to control CVS risk factors rather than glucose (the UKPDS message) NEJM 21 September 2007

Three Way Randomisation 700 T2DM on OAD Add twice daily biphasic insulin * Add once (or twice) daily basal insulin * Add thrice daily prandial insulin * Randomisation visit One year * progress to more intensive insulin regimen only if clinically necessary † stop sulphonylurea if taken Glycaemic target: HbA 1c ≤6.5% R Add midday prandial insulin if glycaemic target not met † Add prandial insulin if glycaemic target not met † Add basal insulin if glycaemic target not met † Two years Three years

Choice is a trade off: different insulin regimens vary but lower HbA1c associated with more adverse effects Conclusion: start low and go slow